Assessing gout risk associated with GLP‐1 therapy in obese patients with type 2 diabetes: A retrospective cohort study
Open Access
- 1 July 2025
- journal article
- Published by Wiley in Rheumatology & Autoimmunity
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- GLP-1 Receptor Agonists: Beyond Their Pancreatic EffectsFrontiers in Endocrinology, 2021
- Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 DiabetesAnnals of Internal Medicine, 2020
- Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trialAnnals of the Rheumatic Diseases, 2017
- GoutThe Lancet, 2016